Activin receptor-like kinase 5 (ALK5) inhibitors: a patent review (2013-present)
Expert Opinion on Therapeutic Patents · 04.05.2026 · 36 (5) · 401-433
DOI: 10.1080/13543776.2026.2660906 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Expert Opinion on Therapeutic Patents, online erschienen am 19.04.2026. Verfasst von Xin-Yi Huang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, College of Pharmacy, Yanbian University, Yanji, China. Hauptthemen laut MEDLINE: Receptor, Transforming Growth Factor-beta Type I, Protein Kinase Inhibitors. Die Arbeit nennt 136 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, College of Pharmacy, Yanbian University, Yanji, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Huang, X. Y., Yu, C. Q., Wang, X., Guo, Z., & Jin, C. H. (2026). Activin receptor-like kinase 5 (ALK5) inhibitors: a patent review (2013-present). Expert Opinion on Therapeutic Patents, 36(5), 401-433. https://doi.org/10.1080/13543776.2026.2660906
Vancouver
Huang XY, Yu CQ, Wang X, Guo Z, Jin CH. Activin receptor-like kinase 5 (ALK5) inhibitors: a patent review (2013-present). Expert Opinion on Therapeutic Patents. 2026;36(5):401-433. doi:10.1080/13543776.2026.2660906
BibTeX
@article{Huang2026,
author = {Huang, Xin-Yi and Yu, Chao-Qun and Wang, Xin and Guo, Zhen and Jin, Cheng-Hua},
title = {Activin receptor-like kinase 5 (ALK5) inhibitors: a patent review (2013-present)},
journal = {Expert Opinion on Therapeutic Patents},
year = {2026},
volume = {36},
number = {5},
pages = {401--433},
doi = {10.1080/13543776.2026.2660906}
}
EUVIMED